Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Cyclin D2 antibody

CCND2 Reactivity: Human, Mouse WB, IP Host: Mouse Monoclonal DCS-3 unconjugated
Catalog No. ABIN487478
  • Target See all Cyclin D2 (CCND2) Antibodies
    Cyclin D2 (CCND2)
    Reactivity
    • 95
    • 50
    • 39
    Human, Mouse
    Host
    • 77
    • 22
    Mouse
    Clonality
    • 80
    • 19
    Monoclonal
    Conjugate
    • 49
    • 6
    • 6
    • 5
    • 4
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This Cyclin D2 antibody is un-conjugated
    Application
    • 75
    • 40
    • 19
    • 15
    • 14
    • 13
    • 13
    • 10
    • 8
    • 8
    • 4
    • 2
    • 2
    • 1
    • 1
    Western Blotting (WB), Immunoprecipitation (IP)
    Specificity
    This antibody reacts with Human and Mouse Cyclin D2.
    Characteristics
    Synonyms: Cyclin-D2, CCND2
    Purification
    Protein-A Sepharose Chromatography.
    Immunogen
    Full-length recombinant Human Cyclin D2 protein. Remarks: Hybridoma was established by fusion of mouse myeloma cell NS-2 with Balb/cmouse splenocyte.
    Clone
    DCS-3
    Isotype
    IgG2a
    Top Product
    Discover our top product CCND2 Primary Antibody
  • Application Notes
    Western blott: 1 μg/mLImmunoprecipitation: 2 μg/200-300 μL of cell extract. Positive Control: NIH/3T3 cells. It is reported that this clone is reactive with several Human cells such as U-2-OS, Bristol-8and Lovo36 (See Reference 1). Detailed procedure is provided in Protocols.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.
    Protocol
    SDS-PAGE & Western Blotting1) Wash the cells 3 times with PBS and suspend with 10 volume of cold Lysis buffer (50 mMTris-HCl, pH 7. 2, 250 mM NaCl, 0. 1% NP-40, 2 mM EDTA, 10% glycerol) containingappropriate protease inhibitors. Incubate it at 4°C with rotating for 30 minutes, thensonicate briefly (up to 10 seconds). 2) Centrifuge the tube at 12,000 x g for 10 minutes at 4°C and transfer the supernatant toanother tube. Measure the protein concentration of the supernatant and add the Lysisbuffer to make 8 mg/mL solution. 3) Mix the sample with equal volume of Laemmli's sample buffer. 4) Boil the samples for 2 minutes and centrifuge. Load 10 μL of the sample per lane in a 1mm thick SDS-polyacrylamide gel for electrophoresis. 5) Blot the protein to a polyvinylidene difluoride (PVDF) membrane at 1 mA/cm2 for 1 hourin a semi-dry transfer system. (Transfer Buffer: 25 mM Tris, 190 mM glycine, 20% MeOH). See the manufacture's manual for precise transfer procedure. 6) To reduce nonspecific binding, soak the membrane in 10% skimmed milk (in PBS, pH7. 2) for 1 hour at RT, or overnight at 4°C. 7) Incubate the membrane with the anti-cyclin D2 monoclonal antibody (1 μg/mL) dilutedwith 1% skimmed milk (in PBS, pH 7. 2) for 1 hour at RT8) Wash the membrane with PBS (5 min x 6 times). 9) Incubate the membrane with the 1: 10000POD-conjugated anti-mouse IgG diluted with 1% skimmed milk (in PBS, pH 7. 2) for 1 h atRT. 10) Wash the membrane with PBS (5 minutes x 6 times)11) Wipe excess buffer on the membrane, then incubate it with appropriatechemiluminescence reagent for 1 minute. Remove extra reagent from the membrane bydabbing with paper towel, and seal it in plastic wrap. 12) Expose to an X-ray film in a dark room for 5 minutes. Develop the film as usual. Thecondition for exposure and development may vary. Positive Control for Western blotting: NIH/3T3Immunoprecipitation1) Wash the cells 3 times with PBS and suspend with 10 volume of cold Lysis buffer (50 mMTris-HCl pH 7. 2, 250 mM NaCl, 0. 1% NP-40, 2 mM EDTA, 10% glycerol) containingappropriate protease inhibitors. Incubate it at 4°C with rotating for 30 minutes, thensonicate briefly (up to 10 seconds)2) Centrifuge the tube at 12,000 x g for 10 min at 4°C and transfer the supernatant toanother tube. 3) Add 2 μg of the anti-cyclin D2 monoclonal antibody into 250 μL of the supernatant. Mixwell and incubate with gentle agitation for 30-120 minutes at 4°C. Add 20 μL of 50%Protein A-agarose beads resuspended in the Lysis buffer. Mix well and incubate with gentleagitation for 60 min at 4°C. 4) Wash the beads 3-5 times with the ice-cold Lysis buffer (centrifuge the tube at 2,500 x gfor 10 seconds). 5) Resuspend the beads in 20 μL of Laemmli’s sample buffer, boil for 3-5 min, andcentrifuge for 5 minutes. Use 10 μL/lane for the SDS-PAGE analysis. (See SDS-PAGE & Western blotting. )
    Restrictions
    For Research Use only
  • Concentration
    1.0 mg/mL
    Buffer
    PBS, pH 7.2 containing 50 % Glycerol without preservatives.
    Preservative
    Without preservative
    Storage
    -20 °C
    Storage Comment
    Store the antibody undiluted at -20 °C.
    Shelf life: one year from despatch.
    Expiry Date
    12 months
  • Target
    Cyclin D2 (CCND2)
    Alternative Name
    Cyclin D2 (CCND2 Products)
    Synonyms
    si:ch211-240j22.2 antibody, ccnd2 antibody, CCND2 antibody, kiak0002 antibody, zgc:162280 antibody, LOC100224096 antibody, KIAK0002 antibody, BF642806 antibody, C86853 antibody, Vin-1 antibody, Vin1 antibody, cD2 antibody, 2600016F06Rik antibody, AI256817 antibody, cyclin D2, b antibody, cyclin D2 S homeolog antibody, cyclin D2 antibody, G1/S-specific cyclin-D2 antibody, cyclin D2, a antibody, cyclin D2 L homeolog antibody, ccnd2b antibody, ccnd2.S antibody, CCND2 antibody, ccnd2 antibody, ccnd2a antibody, Ccnd2 antibody, ccnd2.L antibody
    Background
    Cyclin D2 (34 kDa) is one of three D-type cyclins that are synthesized in G1 phase and induced in response to agents that promote re-entry into the cell cycle. D-type cyclins assemble with cyclin-dependent kinases Cdk4 and Cdk6 to form complexes that phosphorylate key substrates, including the retinoblastoma protein Rb, involved in proliferation. Generally, D cyclins appear late in the G1 phase of the cell cycle, however, cyclin D2 accumulates in Go and at the G1/S interface. A role for cyclin D2 has been suggested in differentiation and oncogenic transformation. Cyclin D2 is expressed in macrophages in response to CSF-1 stimulation, and overexpression of cyclin D2 is associated with increased in vivo invasiveness of human squamous carcinoma cells.Synonyms: CCND2, Cyclin-D2
    Gene ID
    894
    UniProt
    P30279
    Pathways
    Cell Division Cycle, Mitotic G1-G1/S Phases
You are here:
Support